There's sometimes chicken and egg effects that go both directions
Initially concerned about the process, she found the injections manageable with guidance from her healthcare team
Licensing (Marketing Authorisation): The MHRA has approved: Semaglutide (Wegovy) for adults with BMI 30 kg/m or BMI 27 kg/m with at least one weight-related comorbidity Liraglutide (Saxenda) with similar BMI criteria NHS Access (NICE Guidance): According to NICE guidance (TA664 for semaglutide), NHS-funded treatment is more restricted and typically available for adults with: BMI 35 kg/m with at least one weight-related comorbidity (such as hypertension, type 2 diabetes, dyslipidaemia, obstructive sleep apnoea, or cardiovascular disease) For individuals from Black, Asian, and minority ethnic backgrounds, lower BMI thresholds may apply, recognising that these populations face increased metabolic risk at lower BMI levels

Preliminary observations from a Phase III clinical trial (NCT02896192) suggested that among 10 patients with POMC -deficient obesity (aged 6 years, BMI 30 kg/m 2 ), approximately 80% achieved a weight reduction of 10% after 1 year of treatment with setmelanotide following individualized dose titration
Why I Recommend Adenosine + GHK-Cu Micro-Infusion to Every Woman Losing Hair This is the first approach I've seen that delivers consistent results for telogen effluvium specifically